RxDoctor Payments Data

Erika Vucko

Nurse Practitioner · Chicago, ILNPI 1467848366

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 65.9% of it on its own, with 11 other manufacturers making up the rest. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,424in general payments, 2019–2025

Across 184 payments — averaging $415.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$50K
  • Amgen$17K
  • PTC Therapeutics, Inc.$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Sanofi$1K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$867
  • plus $907 from 6 others
$340,872in research payments, 2019–2025

Across 70 payments — averaging $4869.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biomarin Pharmaceutical Inc.$325K
  • Ultragenyx Pharmaceutical Inc.$16K

What the payments were for

  • Consulting fees$14,39019%
  • Speaking & faculty fees$43,63957%
  • Travel & lodging$11,44515%
  • Food & beverage$6,9509%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,424 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Most prescribed under Part D

DrugClaimsCost to plans & patients
PalynziqPegvaliase-Pqpz12$224,061
JavygtorSapropterin Dihydrochloride22$156,638
Sapropterin Dihydrochloride26$113,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Biomarin Pharmaceutical Inc.Palynziq$50,358$224,06112 claims
Cycle Pharmaceuticals IncJavygtor$162$156,63822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →